Actinium Pharmaceuticals, Inc.
(NYSE Amex Equities : ATNM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.41%570.062.7%$662.15m
AMGNAmgen, Inc. -0.64%227.501.3%$583.41m
ILMNIllumina, Inc. 1.00%321.033.5%$561.02m
GILDGilead Sciences, Inc. -0.77%59.751.0%$497.52m
VRTXVertex Pharmaceuticals, Inc. -0.49%210.341.9%$485.95m
MRNAModerna, Inc. 2.84%70.310.0%$485.11m
ARRYArray BioPharma Inc. -0.79%39.0314.2%$474.59m
IMMUImmunomedics, Inc. 0.05%87.8711.0%$373.48m
NVAXNovavax, Inc. 1.18%92.2496.5%$306.38m
ALXNAlexion Pharmaceuticals, Inc. 0.63%118.932.0%$282.17m
BIIBBiogen, Inc. -1.19%265.711.6%$261.45m
EXASEXACT Sciences Corp. 1.33%100.9420.7%$222.48m
BNTXBioNTech SE -1.43%86.470.0%$211.61m
SRNESorrento Therapeutics, Inc. 0.76%7.911.4%$182.71m
SGENSeagen Inc. -0.16%197.396.0%$162.10m

Company Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The firm provides its service through Iomab-B, which is studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company was founded in 2002 and is headquartered in New York, NY.